Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 June, 2018 09:49 IST
Alembic Pharma receives nod for Doxycycline Hyclate capsules
Source: IRIS | 14 Jun, 2018, 11.09AM
Comments  |  Post Comment

Alembic Pharmaceuticals today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Capsules USP, 50 mg and 100 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vibramycin Capsules, 50 mg and 100 mg, of Pfizer Inc. Doxycycline is indicated for a wide variety of bacterial infections including those caused by several gram-negative as well as gram-positive microorganisms. Doxycycline is also indlcated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethaminesulfadoxine resistant strains. Doxycycline may be a useful adjunctive therapy in severe acne and in acute intestinal amebiasis.

Doxycycline Hyclate Capsules USP, 50 mg and 100 mg, have an estimated market size of USD 80 million for twelve months ending December 2017 according to IQVIA.

Alembic now has a total of 73 ANDA approvals (65 final approvals and 8 tentative approvals) from USFDA.

Shares of the company gained Rs 16.2, or 3.16%, to trade at Rs 529.00. The total volume of shares traded was 27,704 at the BSE (10.59 a.m., Thursday).





Alembic Pharmaceuticals Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Dr. Reddy's defends right to launch Buprenorphine and Naloxone Sublingual Film - 18-Jun-2018 12:40
Lupin, Nichi-Iko in pact for commercialisation of Etanercept in Japan - 18-Jun-2018 11:38
Yes Bank gets SEBI approval for offering custodial services - 18-Jun-2018 10:06
Fitch affirms at Axis Bank and ICICI Bank's issuer rating at BBB- - 15-Jun-2018 15:36
Fitch affirms at Axis Bank and ICICI Bank's issuer rating at BBB- - 15-Jun-2018 15:36
Dhunseri Petrochem to exit JV in Egypt with Indorama - 15-Jun-2018 15:22
NBCC bags orders worth Rs 4.80 bn in May 2018 - 15-Jun-2018 15:16
Jammu and Kashmir Bank to raise tier-I capital up to Rs 10 bn - 15-Jun-2018 11:26
Alembic Pharma receives EIR for formulation facility at Panelav - 15-Jun-2018 10:39
MERC reserves order on R-Infra's sale of Mumbai power biz to Adani - 15-Jun-2018 10:16
Dr. Reddy's receives nod for Buprenorphine, Naloxone Sublingual film - 15-Jun-2018 09:50
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer